Dermatology Drugs Market Size Historical Growth, Analysis, Opportunities and Forecast To 2022
PolarisMarketResearch.com adds a new Dermatology Drugs Market research report for the period of 2017-2022 focuses on the major drivers and restraints for the global key players providing analysis of the market share, segmentation, revenue forecasts and ge
(EMAILWIRE.COM, October 24, 2018 ) Polaris Market Research presents a most up-to-date research on Dermatology Drugs Market [(By Therapeutic Area (Atopic Dermatitis, Psoriasis, Acne, Rosacea), By Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), By Approved Treatments (etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx), ixekizumab (Taltz), golimumab (Simponi), brodalumab (Siliq), and guselkamab (Tremfya), and By Region]: Market Size & Forecast, 2017 2022.
Polaris Market Research assumes that with the expected launch of the potential promising therapies, the market is anticipated to expand in both psoriasis and atopic dermatitis segments. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is due to the increased adoption of high-priced biologics. Despite the launch and availability of multiple biologics, only 10% of the patients have access to these treatments and the market continues to remain underpenetrated.
Request a sample report @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-free-sample
Major Key Player in the Report are:
Allergan Plc
Valeant Pharmaceuticals
Dermira Inc
Aclaris Therapeutics, Inc
AnaptysBio, Inc
Revance Therapeutics
Foamix Pharmaceuticals
Novan, Inc
Sienna Biopharmaceuticals
Pfizer
Sanofi
Galderma
Leo Pharma
Roviant Sciences
Otsuka Pharmaceuticals.
Currently, the Dermatology Drugs market is highly fragmented but offer several commercial opportunities. There remains significant unmet need for safer and cost-effective treatment options. Psoriasis market was nearly USD 6 billion markets in 2016 due to the existing effective TNF alpha treatments. In Acne, retinoids and antibiotics are the mainstay treatments but what makes this indication lucrative is the promising candidates in the pipeline including Foamixs FMX-101 and Dermiras DRM-101.
Dermatology Drugs Market, by Region:
North America - U.S., Canada
Europe - Germany, UK, France
Asia-Pacific India, Japan, China
Latin America - Brazil, Mexico
Middle East & Africa
Polaris Market Research has provided the forecasts of the Global Dermatology Drugs Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:
Market Analysis by Dermatology Key Indications
Market Analysis by Treatment Class/Marketed Drugs
Market Analysis by Regions.
Get Customization in the Report, Enquire Now @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market-/inquire-before-buying
The Marketed Therapies undertaken in forecast from 2016-2022 are:
etanercept; Enbrel
infliximab; Remicade
adalimumab; Humira
ustekinumab; Stelara
secukinumab; Cosentyx
ixekizumab; Taltz
golimumab; Simponi
brodalumab; Siliq
guselkamab; Tremfya
Topical Drugs
Oral Antibiotics
The Major Indications in Dermatology Therapy area:
Atopic Dermatitis
Psoriasis
Acne
Rosacea.
Out of all dermatological indications, Psoriasis is the largest with several approved biologics and followed by Acne. Psoriasis affects approximately 8 million patients in the U.S. and roughly 20-30% have moderate to severe psoriasis. Out of them, only 10% of the moderate to severe patients are treated with biologics. Acne is the most commonly treated skin disorders and occurs in adolescents and patients between 15-24 years of age. Despite the size of the market, there is no single best treatment for acne and therefore combinations treatments are often used. Currently, Topical therapies dominate the acne treatment. There remains significant unmet need in the Dermatology drugs market as current treatment options do not offer improved safety, efficacy and tolerability profile often with low patient compliance.
Read More Details @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market-/
About us Polaris Market Research
Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities.
Contact us-
Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
Polaris Market Research assumes that with the expected launch of the potential promising therapies, the market is anticipated to expand in both psoriasis and atopic dermatitis segments. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is due to the increased adoption of high-priced biologics. Despite the launch and availability of multiple biologics, only 10% of the patients have access to these treatments and the market continues to remain underpenetrated.
Request a sample report @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-free-sample
Major Key Player in the Report are:
Allergan Plc
Valeant Pharmaceuticals
Dermira Inc
Aclaris Therapeutics, Inc
AnaptysBio, Inc
Revance Therapeutics
Foamix Pharmaceuticals
Novan, Inc
Sienna Biopharmaceuticals
Pfizer
Sanofi
Galderma
Leo Pharma
Roviant Sciences
Otsuka Pharmaceuticals.
Currently, the Dermatology Drugs market is highly fragmented but offer several commercial opportunities. There remains significant unmet need for safer and cost-effective treatment options. Psoriasis market was nearly USD 6 billion markets in 2016 due to the existing effective TNF alpha treatments. In Acne, retinoids and antibiotics are the mainstay treatments but what makes this indication lucrative is the promising candidates in the pipeline including Foamixs FMX-101 and Dermiras DRM-101.
Dermatology Drugs Market, by Region:
North America - U.S., Canada
Europe - Germany, UK, France
Asia-Pacific India, Japan, China
Latin America - Brazil, Mexico
Middle East & Africa
Polaris Market Research has provided the forecasts of the Global Dermatology Drugs Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:
Market Analysis by Dermatology Key Indications
Market Analysis by Treatment Class/Marketed Drugs
Market Analysis by Regions.
Get Customization in the Report, Enquire Now @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market-/inquire-before-buying
The Marketed Therapies undertaken in forecast from 2016-2022 are:
etanercept; Enbrel
infliximab; Remicade
adalimumab; Humira
ustekinumab; Stelara
secukinumab; Cosentyx
ixekizumab; Taltz
golimumab; Simponi
brodalumab; Siliq
guselkamab; Tremfya
Topical Drugs
Oral Antibiotics
The Major Indications in Dermatology Therapy area:
Atopic Dermatitis
Psoriasis
Acne
Rosacea.
Out of all dermatological indications, Psoriasis is the largest with several approved biologics and followed by Acne. Psoriasis affects approximately 8 million patients in the U.S. and roughly 20-30% have moderate to severe psoriasis. Out of them, only 10% of the moderate to severe patients are treated with biologics. Acne is the most commonly treated skin disorders and occurs in adolescents and patients between 15-24 years of age. Despite the size of the market, there is no single best treatment for acne and therefore combinations treatments are often used. Currently, Topical therapies dominate the acne treatment. There remains significant unmet need in the Dermatology drugs market as current treatment options do not offer improved safety, efficacy and tolerability profile often with low patient compliance.
Read More Details @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market-/
About us Polaris Market Research
Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities.
Contact us-
Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
Contact Information:
Polaris Market Research
Neel
Tel: +1-646-568-9980
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Polaris Market Research
Neel
Tel: +1-646-568-9980
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results